Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BG00002 (natalizumab), interferon beta-1a, glatiramer acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: BIO-11006, Placebo; Drug
Lead sponsor: BioMarck Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Age-related Volume Deficit in the Mid-face
Interventions: JUVÉDERM VOLUMA® XC injectable gel with cannula, JUVÉDERM VOLUMA® XC injectable gel with needle; Device
Lead sponsor: Allergan; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Los Angeles, California • Solana Beach, California • Miami, Florida + 4 more

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Triple-Negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Atezolizumab Placebo, Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Stanford, California • Fort Myers, Florida • St. Petersburg, Florida + 5 more

Conditions: Parkinson's Disease
Interventions: pramipexole; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Paranoia, Psychotic Disorders
Interventions: Guided Visual Imagery Task; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Bipolar Disorder
Interventions: L-Thyroxine, Placebo; Drug
Lead sponsor: Charite University, Berlin, Germany; Other
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: HIV I Infection
Interventions: VIR-1111, Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Seattle, Washington • Madison, Wisconsin

Conditions: Prevention of Travelers' Diarrhea
Interventions: heat-labile enterotoxin of E. coli (LT), Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Vallejo, California • South Miami, Florida • San Antonio, Texas

Conditions: Major Depressive Disorder
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 53
States / cities: Rogers, Arkansas • Bellflower, California • Garden Grove, California + 44 more

Conditions: Familial Amyloid Polyneuropathy
Interventions: Fx-1006A, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
Interventions: Wide Local Excision; Diagnostic Test
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Menopause
Interventions: ACTH; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia
Interventions: inhaled nitric oxide, oxygen; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 2 Hours to 72 Hours
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Low Back Pain
Interventions: Intracept Treatment, Sham Treatment; Device
Lead sponsor: Relievant Medsystems, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Daly City, California • Long Beach, California + 10 more

Conditions: Heart Murmur
Interventions: Self-Study using MP3 Player, Multimedia Lecture; Other
Lead sponsor: The Reading Hospital and Medical Center; Other
Eligibility: Not listed
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: West Reading, Pennsylvania

Conditions: Parkinson Disease
Interventions: STN DBS 10Hz, STN DBS 130Hz, STN DBS off; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Insulin Resistance
Interventions: Novel dietary fiber, Placebo; Other
Lead sponsor: Cargill; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions: Xembify, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more

Conditions: Neurogenic Bladder, Multiple Sclerosis, Overactive Bladder
Interventions: Magstim Rapid2 System; Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia, Memory Disorders, Cognition Disorders
Interventions: Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing, Placebo; Drug · Procedure
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

Racial Disparities in the Expression of Paranoia

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

Traveler's Diarrhea (TD) Automated Process

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma

Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain

Study of Two Teaching Techniques to Teach Cardiac Auscultation to Physicians

Low Frequency Subthalamic Nucleus Deep Brain Stimulation to Improve Verbal Fluency

Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype